Pricing & Market Access

30 March -1 April 2020 | Business Design Centre London

 

 

2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams

 

 

Pricing & Market Access

PRICING & MARKET ACCESS, Monday 30 March 2020

PRE-CONFERENCE WORKSHOP DAY - Monday 30th March 2019

12:00

Networking Lunch

14:45

Afternoon Networking Break

17:30

Close of Conference for the day - Opening Networking drinks reception at the Business Design Center

last published: 04/Jun/20 09:25

PRICING & MARKET ACCESS, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

08:45

Welcome – Jessica Robinson, Project Director, Advanced Therapies 2020, Terrapinn

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
Bradley Campbell
10:00

Importance of patient focus in developing gene therapy for rare diseases

10:20

Morning Coffee Break

Martin Pule
11:20

Keynote presentation: War in the Blood - the latest in the front line of CAR-T clinical research

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

10. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

16. Industrialisation of ATMPs
Mark Lowdell

Mark Lowdell, Chief Scientific Officer, Inmunebio

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, BOKU

21. Neurological applications for ATMPs
John Isaac

John Isaac, Senior Director, External Scientific Innovation And Neuroscience, Johnson & Johnson

22. Development of regenerative medicines for cardiovascular indications
David Mazzo

David Mazzo, Chief Executive Officer, Caladrius Biosciences

3. Ensuring safe delivery to patients and fast time-to-market of advanced therapies - How to address challenges of drug administration, fill & finish, packaging & stability?
Diana Lober

Diana Lober, Product Manager, Schott AG

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

7. Reserved for Fujifilm Diosynth Biotechnology
13:00

Lunch

EVIDENCE, PRICING AND MARKET ACCESS

Chair: Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Mike Fraser
PRICING & MARKET ACCESS
14:20

Pricing and market access of gene therapies

Mike Fraser, Head of EMEA Region, AveXis
Darren Walsh
PRICING & MARKET ACCESS
14:40

Addressing unique commercial challenges with gene therapy: learnings from Strimvelis

Axel Boehnke
PRICING & MARKET ACCESS
15:00

Recent developments on Gene Therapy in Germany

  • HTA: Recent developments and processes so far
  • Reimbursement: Contracting models and implementations
  • Data-requirements / registries – an outlook
Sheela Upadhyaya
PRICING & MARKET ACCESS
15:20

Updates on reimbursement and market access strategies for ATMPs in the UK

Paolo Morgese
PRICING & MARKET ACCESS
15:40

Getting ready: ARM and access to ATMPs in Europe

  • Access status and expectations for the years to come
  • Challenges and solutions identified by stakeholders
  • RWE infrastructure and new payment models
16:20

Afternoon Break

Panel discussion
PRICING & MARKET ACCESS
17:00

Panel discussion: Finding the right framework for reimbursement and market access for cell and gene therapies

  • Updates on current EU pricing and contracts for Kymriah, Yescarta and Luxturna
  • Structured reimbursement system for hospital-based treatments in Europe: how is this working so far in 2020?
  • How should be looking at transformative therapy pricing in the next 5 years?
  • What is possible for statutory health insurance framework in the EU?
Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)
Steven M Altschuler, Chair, Board Of Directors, Spark Therapeutics
18:00

Close of Conference for the day - Please join us for an evening drinks reception

last published: 04/Jun/20 09:25